Business Context and Reporting Period
Company: Alphatec Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 15, 2009
Reporting Period: Events occurring on April 15 and April 16, 2009, with agreements effective as of March 31, 2009.
Alphatec Holdings, Inc. and its wholly owned subsidiary, Alphatec Spine, Inc., entered into amended and restated agreements with Stout Medical Group LP ("Stout") regarding intellectual property licenses and developmental consulting services.
Key Financial Metrics and Agreements
This filing details material definitive agreements rather than standard financial performance metrics. Key financial terms include:
- Consulting Fee Adjustment: Under the Amended and Restated Consulting Agreement, Stout is obligated to return $400,000 in previously paid consulting fees to Alphatec.
- Future Consulting Obligations: Alphatec is obligated to pay $20,000 per month for 12 months, commencing in July 2009.
- Equity Retention: Stout retains 101,944 shares of restricted stock previously issued by Alphatec, subject to vesting upon attainment of development milestones.
- Royalty Obligations: Minimum royalty obligations under the license agreements have been tolled (delayed) until licensed products obtain regulatory approval from the FDA.
Material Changes Versus Prior Period
The filing outlines significant modifications to agreements originally entered into in March 2008 and September 2007:
- License Agreement (Expandable Interbody Device):
- Prior Term: Minimum royalty obligation began for the year ending December 31, 2010.
- New Term: Minimum royalty obligation is tolled until FDA regulatory approval is obtained.
- Termination: Stout's ability to terminate was revised; termination can be delayed by Alphatec through specific payments if a regulatory filing is made.
- License Agreement (Vertebral Compression Fractures):
- Prior Term: Minimum royalty obligation began for the year ending December 31, 2009.
- New Term: Minimum royalty obligation is tolled until FDA regulatory approval is obtained.
- Termination: Stout may terminate if Alphatec does not use commercially reasonable efforts to obtain approval, subject to delay via payments.
- Consulting Agreement:
- Prior Term: Ten monthly payments of $50,000 (Total $500,000).
- New Term: Ten monthly payments of $20,000 for 12 months (Total $240,000), with $400,000 of prior payments to be returned.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The amendments align financial obligations with regulatory milestones, reducing immediate cash outflows for royalties and adjusting consulting fees to reflect current development needs.
Risks and Contingencies:
- Regulatory Approval Risk: The tolling of royalty payments is contingent upon obtaining FDA clearance. Failure to obtain approval may impact the commercialization timeline.
- Termination Risk: Stout retains the right to terminate the license agreements if Alphatec fails to file for regulatory approval within allotted time periods, unless Alphatec makes specific payments to delay termination.
- Development Milestones: The vesting of 101,944 restricted shares held by Stout is contingent on achieving specific development milestones.
Important Facts for Investor Verification
- Verify the return of the $400,000 consulting fee from Stout to Alphatec in upcoming cash flow statements.
- Monitor the status of FDA regulatory filings for the expandable interbody device and vertebral compression fracture treatment to assess royalty tolling status.
- Review the full text of the Amended and Restated License and Consulting Agreements, which are filed as exhibits to the Form 10-Q for the quarter ended March 31, 2009.
- Track the vesting schedule of the 101,944 restricted shares held by Stout.